Mean baseline hemoglobin concentration on admission to the ICU was 11.0 ± 2.4 g/dl, and mean hemoglobin decreased to 9.8 ± 1.4 g/dl by the end of the study (P < 0.0045).
Among C282Y-homozygous males, the mean hemoglobin decreased by 6.0 g/L (p < 0.0001, paired t-test).
Among compound-heterozygous males, the mean hemoglobin decreased by 9.9 g/L (p < 0.0001, paired t-test); one patient (4.8%) had a rise in posttreatment hemoglobin and 2 patients had no change in their hemoglobin levels.
Similar results were also observed among C282Y-homozygous females; the mean hemoglobin decreased by 5.1 g/L (p < 0.0001, paired t-test); posttreatment hemoglobin levels decreased in 52 patients (72.2%), increased in 17 patients (23.6%), and remained unchanged in 3 patients.
Overall in the ITT population, mean hemoglobin concentrations decreased versus baseline from Day 1 for both treatment groups (Figure 2a), and were slightly lower for CDA versus AL on Days 3, 7 and 14 (Figure 2a).
Between 1995 and 1996, when the food supplementation was reduced, mean hemoglobin concentrations decreased at all residential exposure levels except the middle level, 128 218 kBq/m.
In both HIV-infected and uninfected babies, mean hemoglobin concentration decreased dramatically from birth to 6 weeks, in a pattern consistent with the postnatal physiologic decline, but did not rise again.
UC mean glycated hemoglobin decreased 0.7% (0.3 1.1).
CPDS mean glycated hemoglobin decreased 1.9%9595% CI 1.5 2.3) over 12 months.
Thus, the placebo-corrected mean glycated hemoglobin decrease was −0.11, −0.44, and −0.85% after 1, 2, and 3 months, respectively, between the intermediate-dose and placebo/low-dose groups.
